{
    "article_link": "https://doi.org/10.1038/s41586-021-04278-5",
    "data": [
        {
            "id": "data_1",
            "omics": "Genomics",
            "link": "https://ega-archive.org/",
            "format": "VCF",
            "source": "European Genome-Phenome Archive (EGA)",
            "public_id": "EGAS00001004582"
        },
        {
            "id": "data_2",
            "omics": "Transcriptomics",
            "link": "https://ega-archive.org/",
            "format": "BAM",
            "source": "European Genome-Phenome Archive (EGA)",
            "public_id": "EGAS00001004582"
        },
        {
            "id": "data_3",
            "omics": "Digital Pathology",
            "link": "",
            "format": "TPM gene expression derived from digital pathology",
            "source": "Cambridge University Hospitals NHS Foundation Trust",
            "public_id": null,
            "note": "Data not publicly available"
        },
        {
            "id": "data_4",
            "omics": "Clinical",
            "link": "",
            "format": "Clinical Metadata (Excel)",
            "source": "Cambridge University Hospitals NHS Foundation Trust",
            "public_id": null,
            "note": "Data not publicly available",
            "features": [
                "Tumor grade",
                "ER status",
                "HER2 status",
                "Lymph node involvement"
            ]
        },
        {
            "id": "data_5",
            "omics": "Gene Sets",
            "link": "https://www.gsea-msigdb.org/",
            "format": "Curated gene set",
            "source": "MSigDB",
            "public_id": "MSigDB_v6.1"
        },
        {
            "id": "data_6",
            "omics": "Gene Sets",
            "link": "https://reactome.org/",
            "format": "Curated gene set",
            "source": "Reactome",
            "public_id": null
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Differential gene expression analysis",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_2",
            "analysis_name": "Gene set enrichment analysis (GSEA)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_3",
            "analysis_name": "Copy number calling",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_4",
            "analysis_name": "Mutational signature decomposition",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_5",
            "analysis_name": "HLA typing and neoantigen calling",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "iC10 classification",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_7",
            "analysis_name": "Multi-omic Ensemble Machine Learning Model (Logistic Regression, SVM, Random Forest)",
            "analysis_data": [
                "data_1",
                "data_2",
                "data_3",
                "data_4"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_8",
            "analysis_name": "Clinical feature selection",
            "analysis_data": [
                "data_4"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "GGI enrichment analysis (GSVA)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_10",
            "analysis_name": "Embryonic stem-cell metagene analysis",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_11",
            "analysis_name": "STAT1 immune signature analysis",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_12",
            "analysis_name": "T cell dysfunction analysis (TIDE)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "HER2_status": [
                    "HER2−"
                ],
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_13",
            "analysis_name": "T cell exclusion analysis (TIDE)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "HER2_status": [
                    "HER2−"
                ],
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_14",
            "analysis_name": "Subclonal Mutation Analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_15",
            "analysis_name": "Tumor mutation burden (TMB) analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_16",
            "analysis_name": "Mutational signature stratification by HER2 status",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "HER2_status": [
                    "HER2−",
                    "HER2+"
                ]
            }
        },
        {
            "id": "analysis_17",
            "analysis_name": "Unsupervised hierarchical clustering of immune cell abundance",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_18",
            "analysis_name": "Digital pathology feature extraction",
            "analysis_data": [
                "data_3"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_19",
            "analysis_name": "Cross-validation performance",
            "analysis_data": [
                "analysis_7"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_20",
            "analysis_name": "Simulation study for clinical impact",
            "analysis_data": [
                "analysis_7"
            ],
            "label": {
                "False negatives (FN)": [
                    "0",
                    "2"
                ]
            }
        },
        {
            "id": "analysis_21",
            "analysis_name": "Taxane response metagene analysis",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "HER2_status": [
                    "HER2−",
                    "HER2+"
                ]
            }
        },
        {
            "id": "analysis_22",
            "analysis_name": "Digital pathology immune deconvolution (Danaher, MCPcounter, Immunophenoscore)",
            "analysis_data": [
                "data_3",
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_1",
            "metrics": "Odds ratio (OR), Confidence interval (CI), P-value",
            "value": "TP53: OR=2.9, CI=1.3–6.6, P=0.01; PIK3CA: OR=2.1, CI=1.3–3.4, P=0.002",
            "features": [
                "EGFR overexpression",
                "MYC overexpression",
                "CCNE1 overexpression",
                "CDKN2A overexpression",
                "CCND1 underexpression",
                "ZNF703 underexpression",
                "ESR1 underexpression"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Normalized enrichment score",
            "value": "Proliferation: P=0.0005; Immune activation: P=0.001",
            "features": [
                "E2F targets",
                "MYC targets v1",
                "IFNγ response",
                "G2M checkpoint",
                "MTORC1 signaling",
                "Tumor necrosis factor (TNF) signaling via NF-κB",
                "Inflammatory response",
                "Mitotic spindle"
            ]
        },
        {
            "analysis_id": "analysis_3",
            "metrics": "P-value",
            "value": "P=0.0002",
            "features": [
                "Copy number alterations",
                "Chromosomal instability"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Odds ratio (OR), P-value",
            "value": "HRD: OR=1.1, P=0.006; APOBEC: OR=1.1, P=0.02",
            "features": [
                "HRD score",
                "APOBEC signature",
                "BRCA signature",
                "Chromosomal instability"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Odds ratio (OR), Confidence interval (CI), P-value",
            "value": "HLA class I locus LOH: OR=3.5, CI=1.1–14.2, P<0.05; 69% of LOH events targeted HLA alleles critical for neoantigen presentation",
            "features": [
                "HLA class I locus LOH",
                "Neoantigen load"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "Pearson residuals",
            "value": "iC10: overrepresented in pCR; iC3, iC7, iC8: underrepresented in pCR",
            "features": [
                "iC10 subtypes",
                "iC3 subtypes",
                "iC7 subtypes",
                "iC8 subtypes"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "AUC, Bootstrap standard deviation",
            "value": "AUC (training)=0.86, AUC (validation)=0.87; Bootstrap SD (training)=0.05, Bootstrap SD (validation)=0.05",
            "features": [
                "Age",
                "Lymphocyte density",
                "PGR expression",
                "ESR1 expression",
                "ERBB2 expression",
                "Tumor mutation burden (TMB)",
                "HRD score",
                "GGI score",
                "STAT1 score",
                "Chromosomal instability",
                "Anthracycline therapy",
                "Anti-HER2 therapy",
                "Taxane therapy",
                "Number of chemotherapy cycles",
                "Therapy sequence"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": "AUC",
            "value": "AUC=0.70",
            "features": [
                "Tumor grade",
                "ER status",
                "HER2 status",
                "Lymph node involvement"
            ]
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "GSVA score",
            "value": "GGI score: enrichment score pCR vs. RCB-III; STAT1 score: enrichment score pCR vs. RCB-III",
            "features": [
                "GGI score",
                "STAT1 score"
            ]
        },
        {
            "analysis_id": "analysis_10",
            "metrics": "Wilcoxon rank-sum test (two-sided)",
            "value": "T cell dysfunction: P=0.006 (HER2−); T cell exclusion: P=0.02 (HER2−)",
            "features": [
                "T cell dysfunction score",
                "T cell exclusion score"
            ]
        },
        {
            "analysis_id": "analysis_11",
            "metrics": "Ordinal logistic regression P-value",
            "value": "P=1×10−6 (validation)",
            "features": [
                "Predictor score"
            ]
        },
        {
            "analysis_id": "analysis_12",
            "metrics": "Odds ratio (OR), P-value",
            "value": "HRD: OR=1.1, P=0.006; APOBEC: OR=1.1, P=0.02",
            "features": [
                "HRD score",
                "APOBEC signature",
                "BRCA signature",
                "Chromosomal instability"
            ]
        },
        {
            "analysis_id": "analysis_13",
            "metrics": "TMB comparison",
            "value": "TMB pCR: 2.3, residual disease: 1.4, P=0.0005",
            "features": [
                "Tumor mutation burden (TMB)"
            ]
        },
        {
            "analysis_id": "analysis_14",
            "metrics": "Percentage of subclonal mutations, P-value",
            "value": "Subclonal mutations higher in residual disease (P=0.04, pCR vs RCB-II); clonally diverse tumors more likely to harbor resistant subclones",
            "features": [
                "Subclonal mutations",
                "Clonal diversity"
            ]
        },
        {
            "analysis_id": "analysis_15",
            "metrics": "PCA clustering pattern",
            "value": "Distinct clustering of immune cell types in pCR vs. residual disease",
            "features": [
                "CD8 T cell enrichment",
                "Regulatory T cells",
                "Mast cells",
                "Cancer-associated fibroblasts",
                "Inhibitory NK CD56dim cells"
            ]
        },
        {
            "analysis_id": "analysis_16",
            "metrics": "Average precision, Area under precision-recall curve",
            "value": "Average precision=0.68; Area under precision-recall curve=0.67",
            "features": [
                "STAT1 immune signature",
                "GGI score",
                "Embryonic stem-cell metagene"
            ]
        },
        {
            "analysis_id": "analysis_17",
            "metrics": "Feature contribution weight",
            "value": "RNA features accounted for the largest contribution to model performance",
            "features": [
                "GGI score",
                "STAT1 score",
                "Lymphocyte density",
                "RNA expression profiles",
                "Mutational landscapes"
            ]
        },
        {
            "analysis_id": "analysis_18",
            "metrics": "Density parameter, Nearest neighbor distance",
            "value": "Lymphocyte density calculated using N=50 nearest neighbors; density parameter independent of N",
            "features": [
                "Lymphocyte density",
                "Cellular fractions",
                "Distance to Nth nearest neighbor"
            ]
        },
        {
            "analysis_id": "analysis_19",
            "metrics": "Cross-validation AUC",
            "value": "Fivefold cross-validation AUC=0.86; Hyperparameters optimized for AUC maximization",
            "features": [
                "Logistic regression",
                "SVM",
                "Random forest"
            ]
        },
        {
            "analysis_id": "analysis_20",
            "metrics": "Number of non-responders identified",
            "value": "Clinical model: 15 non-responders (FN=0); Integrated model: 31 non-responders (FN=0); Clinical model: 24 non-responders (FN=2); Integrated model: 52 non-responders (FN=2)",
            "features": [
                "Predictor score",
                "False negatives (FN)"
            ]
        },
        {
            "analysis_id": "analysis_21",
            "metrics": "Wilcoxon rank-sum test (two-sided)",
            "value": "HER2− tumors with pCR had higher enrichment scores (P=5×10−7)",
            "features": [
                "Taxane response metagene",
                "Proliferation metagene",
                "Ceramide metagene"
            ]
        },
        {
            "analysis_id": "analysis_22",
            "metrics": "Immune cell enrichment scores",
            "value": "CD8 T cell enrichment score pCR: 2.1, residual disease: 3.4, P=0.0001",
            "features": [
                "CD8 T cell enrichment",
                "Regulatory T cells",
                "Mast cells",
                "Cancer-associated fibroblasts",
                "Inhibitory NK CD56dim cells"
            ]
        }
    ]
}